Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase III, Randomized, Double-Blind, Single-Dose, Placebo-Controlled Study to Demonstrate the Efficacy and Safety of Tildrakizumab in Subjects With Active Psoriatic Arthritis I (INSPIRE 1)

NCT04314544 is registered in ClinicalTrials.gov with Sun Pharmaceutical Industries Limited as lead sponsor.

NCT NCT04314544
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04314544 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase III, Randomized, Double-Blind, Single-Dose, Placebo-Controlled Study to Demonstrate the Efficacy and Safety of Tildrakizumab in Subjects With Active Psoriatic Arthritis I (INSPIRE 1)
Lead sponsor
Sun Pharmaceutical Industries Limited
Phase
Phase 3
Overall status
Completed
Start date
July 1, 2020
Completion date
December 22, 2025
Enrollment
508 (actual)
Sites
97

Conditions

As the registry lists them; a condition with its own page is linked.

active psoriatic arthritis